Is Moderna Building a Respiratory Vaccine Empire?
(NASDAQ: MRNA) made a name for itself through its coronavirus vaccine. It's the biotech's first and only product -- and harnesses the company's core messenger RNA technology. The vaccine has generated billions of dollars in earnings over the past two years.
Now, however, demand from that star product is on the decline -- and Moderna faces a serious drop in revenue. This has been worrying investors, weighing on the stock price.
But what if I told you the coronavirus vaccine may be only the start of the Moderna story? This innovative biotech has branched out -- and it could be on its way to creating a respiratory vaccine empire.
Source Fool.com
Moderna Inc. Stock
€116.14
-0.960%
With 16 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 125 € shows a slightly positive potential of 7.63% compared to the current price of 116.14 € for Moderna Inc..
